Application of the AMeX method to the evaluation of HER-2 status in breast carcinomas: Comparison with the results of HercepTest

Pathology International

Volumn 53, Issue 1, 2003, Pages 27-29

  Mizogami, Masayo ^a   Sakurai, Shinji ^a   Kikuchi, Midori ^a   Ohta, Kenichi ^a   Sakurai, Tatsuo ^a   Tanaka, Akira ^a   Saito, Ken ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

AMeX method; Breast carcinoma; FISH; Her2 neu; HercepTest; Immunohistochemistry

Indexed keywords

ACETONE; METHANOL; MONOCLONAL ANTIBODY; XYLENE;

ACCURACY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENES, ERBB-2; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; REAGENT KITS, DIAGNOSTIC; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0037280380     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01429.x     Document Type: Article

References (15)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
2. Fukushige S, Matsubara K, Yoshida M et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-88.
3. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
4. Vogel C, Cobleigh M, Tripathy D et al. First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab humanized anti-HER2 antibody) [Abstract]. Proc Am Soc Clin Oncol 2000; 18: 71A.
5. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
6. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization. Pathology 2001; 33: 278-82.
7. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-75.
8. Labeau A, Deimling D, Kaltz C et al. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-63.
9. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for Trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
10. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001; 14: 1079-86.
11. Tsuda H, Sasano H, Akiyama F et al. Evaluation of interobserver agreement in scoring immunohistochemistry results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int 2002; 52: 126-34.
12. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001; 115: 44-58.
13. Hyytinen E, Visakorpi T, Kallioniemi A et al. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry 1994; 16: 93-9.
14. Kitayama Y, Igarashi H, Sugimura H. Initial intermittent microwave irradiation for fluorescence in situ hybridization analysis in paraffin-embedded tissue sections of gastrointestinal neoplasia. Lab Invest 2000; 80: 779-81.
15. Sato Y, Mukai K, Matsuno Y, Furuya S et al. The AMeX method: A multipurpose tissue-processing and paraffin-embedding method. Am J Pathol 1990; 136: 267-71.